Loading stock data…
Imunon, Inc. (IMNN)
$1.51-0.15 (-9.04%)
Market ClosedLast close Jul 24
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Imunon, Inc. in the Healthcare sector is trading at $1.51 with a market capitalization of $9M. Wall Street consensus targets $17.00 (5 analysts), implying a +1025.8% move over the next 12 months. The stock is currently near its 52-week low of $1.51, remaining 52.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1025.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 23) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.31M↓ | -$4.26M↓ | -$3.48M↓ | -$2.77M↑ | -$4.15M |
| Net Income | -$4.25M↓ | -$4.22M↓ | -$3.43M↓ | -$2.74M↑ | -$4.10M |
Peer Comparison
JNJUNHPFE
Fundamentals
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the loca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.82M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.03
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-435.81%
Volume
Today's trading volume
91,007
Recent News
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients
Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 minimal residual disease (MRD) translational trial. MRD refers to the small number of cancer cells that remain in the body during or after treatment. The data showed that patients receiving IMNN-001 alongside standard-of-care chemotherapy and bevacizumab demonstrated lower rates of residual disease and higher circulating tumor DNA (ctDNA) clearance than those receiving standard treatment alone. The mu
Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)
Imunon Inc. (NASDAQ:IMNN) traded higher in premarket dealings on Thursday after announcing a $10 million financing package that will support the continued development of its lead ovarian cancer programme.
Imunon IMNN Q4 2025 Earnings Transcript
Stacy Lindborg: Thank you, Peter, and good morning, everyone. Joining me on the call this morning is Dr. Douglas Faller, our Chief Medical Officer; and Mr. Jeff Church, our Interim Chief Financial Officer, who likely needs no introduction given his tenure with Imunon.
Imunon Inc (IMNN) Q1 2026 Earnings Call Highlights: Promising Clinical Progress Amidst Funding ...
Imunon Inc (IMNN) reports strong advancements in its Ovation 3 study, despite facing a tough capital funding environment.
Imunon (IMNN) Q1 2026 Earnings Transcript
Stacy R. Lindborg: Thank you. During today's call, management will be making forward-looking statements regarding Immuneon's expectations and projections about future events. In general, forward-looking statements can be identified by words such as expects, anticipates, believes, or other similar expressions.